Cocrystal Pharma (COCP) Income from Discontinued Operations (2012 - 2013)
Cocrystal Pharma's (COCP) quarterly Income from Discontinued Operations came in at -$8.9 million in Q4 2013, down 1924.76% year-over-year from $485611.4 in Q4 2012, and down 13933.13% quarter-over-quarter from $64058.0 in Q3 2013.
Powered by 
Analysis
Cocrystal Pharma (COCP) Income from Discontinued Operations (2012 - 2013) Analysis & Trends
Cocrystal Pharma has disclosed Income from Discontinued Operations across 2 years of filings, most recently posting -$8.9 million for Q4 2013.
- In Q4 2013, Income from Discontinued Operations fell 1924.76% year-over-year to -$8.9 million; the TTM figure through Dec 2013 stood at -$9.2 million (changed N/A YoY), while the FY2013 annual figure was -$8.6 million, down 2493.9% from the prior year.
- Income from Discontinued Operations came in at -$8.9 million for Q4 2013 at Cocrystal Pharma, down from $64058.0 in the prior quarter.
- In the past five years, Income from Discontinued Operations ranged from a high of $64058.0 in Q3 2013 to a low of -$8.9 million in Q4 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Cocrystal Pharma | 16.82 Mn | 14.50 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2013 | -8.86 Mn |
| Sep 30, 2013 | 64,058.00 |
| Dec 31, 2012 | -437,644.00 |
| Sep 30, 2012 | 23,810.00 |